Synaptogenix Phase 2 trial of Bryostatin-1 fails to meet primary endpoint in advanced Alzheimer's

TAO Synergies Inc.

Primary endpoint: change in SIB total score at week 28; Bryostatin-1 1.4 pts vs placebo 0.6 pts, not statistically significant.
Company disappointed, conducting full data review; will provide update on next steps.
Cash position of ~$38.5M (~$4.00 per share) as of Dec 15, 2022, provides flexibility.
Trial was NIH-sponsored, double-blind, placebo-controlled for advanced Alzheimer's disease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.